

University of Groningen

## **Intricate crosstalk between MYC and non-coding RNAs regulates hallmarks of cancer**

Swier, Lotteke J. Y. M.; Dzikiewicz-Krawczyk, Agnieszka; Winkle, Melanie; van den Berg, Anke; Kluiver, Joost

*Published in:*  
Molecular oncology

*DOI:*  
[10.1002/1878-0261.12409](https://doi.org/10.1002/1878-0261.12409)

**IMPORTANT NOTE:** You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2019

[Link to publication in University of Groningen/UMCG research database](#)

### *Citation for published version (APA):*

Swier, L. J. Y. M., Dzikiewicz-Krawczyk, A., Winkle, M., van den Berg, A., & Kluiver, J. (2019). Intricate crosstalk between MYC and non-coding RNAs regulates hallmarks of cancer. *Molecular oncology*, 13(1), 26-45. <https://doi.org/10.1002/1878-0261.12409>

### **Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### **Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

# Intricate crosstalk between MYC and non-coding RNAs regulates hallmarks of cancer

Lotteke J. Y. M. Swier<sup>1</sup>, Agnieszka Dzikiewicz-Krawczyk<sup>2</sup>, Melanie Winkle<sup>1</sup>, Anke van den Berg<sup>1</sup> and Joost Kluiver<sup>1</sup>

<sup>1</sup> Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, The Netherlands

<sup>2</sup> Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland

## Keywords

lncRNA; miRNA; MYC; ncRNA

## Correspondence

J. Kluiver, Department of Pathology and Medical Biology, University Medical Center Groningen, Hanzplein 1, 9700RB Groningen, The Netherlands  
Fax: +31 50 3619107  
Tel: +31 50 3619559  
E-mail: j.l.kluiver@umcg.nl

Lotteke J. Y. M. Swier and Agnieszka Dzikiewicz-Krawczyk should be considered as cofirst authors

(Received 8 August 2018, revised 10 October 2018, accepted 23 October 2018, available online 5 December 2018)

doi:10.1002/1878-0261.12409

Myelocytomatosis viral oncogene homolog (MYC) plays an important role in the regulation of many cellular processes, and its expression is tightly regulated at the level of transcription, translation, protein stability, and activity. Despite this tight regulation, MYC is overexpressed in many cancers and contributes to multiple hallmarks of cancer. In recent years, it has become clear that noncoding RNAs add a crucial additional layer to the regulation of MYC and its downstream effects. So far, twenty-five micro-RNAs and eighteen long noncoding RNAs that regulate MYC have been identified. Thirty-three miRNAs and nineteen lncRNAs are downstream effectors of MYC that contribute to the broad oncogenic role of MYC, including its effects on diverse hallmarks of cancer. In this review, we give an overview of this extensive, multilayered noncoding RNA network that exists around MYC. Current data clearly show explicit roles of crosstalk between MYC and ncRNAs to allow tumorigenesis.

## 1. Introduction

The *MYC* gene family consist of three members, that is, c-MYC, n-MYC, and l-MYC. c-MYC forms a central hub in all cells by regulating many cellular processes, while n-MYC and l-MYC are more tissue-specific regulators. MYC proteins are overexpressed in more than half of all human cancers, including lung, breast, and colon cancers (Albihn *et al.*, 2010). This overexpression is caused by diverse mechanisms including amplifications, translocations, and epigenetic alterations (Kalkat *et al.*, 2017). In this review, we will focus on c-MYC, hereafter referred to as MYC.

MYC belongs to the basic helix–loop–helix superfamily and functions as a transcription factor. Upon dimerization with its binding partner MAX, the MYC-MAX dimer binds to E-box sequences in the promoter region of its targets genes, thereby activating transcription of

these genes (Tu *et al.*, 2015). In addition to interacting with MAX, MYC can also interact with other transcription factors, histone-modifying enzymes, and DNA methyltransferases to repress transcription. MYC regulates the transcription of many different genes, which include protein-coding as well as noncoding genes (Dang, 2012; Hart *et al.*, 2014; Winkle *et al.*, 2015). These noncoding genes can include various RNA molecules, for example, miRNAs and lncRNAs.

miRNAs are noncoding, regulatory RNA molecules of about 22 nucleotides in length. A miRNA is transcribed as a longer primary transcript, which is processed in two steps into a mature single-stranded miRNA and subsequently incorporated into the RISC. The miRNA guides the RISC complex to its target mRNA by recognition of a complementary sequence, most often in the 3' UTR. Usually, conserved Watson–Crick pairing with nucleotides 2–7 of the miRNA,

the so-called seed region, is essential for target recognition (Bartel, 2009). Binding to the target mRNA will subsequently result in mRNA cleavage by AGO2 in case the miRNA has high complementarity with the binding site region on the mRNA. In case of a low level of complementarity, binding will lead to translational repression.

LncRNAs are defined as noncoding RNA molecules of more than 200 nucleotides in length. Their expression is often tissue specific or cell type specific, and their transcripts can have subcellular compartment-specific localizations. Together, this restricts their function to specific cell types and locations. LncRNAs can regulate gene expression at the transcriptional and post-transcriptional level, as well as by modulating protein stability, localization, and functionality via diverse mechanisms. In the nucleus, lncRNAs can regulate transcription of nearby genes in *cis* or of more distant genes in *trans*, for example, by recruiting transcription factors, chromatin-modifying complexes, or heterogeneous nuclear ribonucleoprotein (hnRNP) complexes. LncRNAs residing in the cytoplasm can modulate mRNA stability, translation efficiency, or protein stability, localization, or

activity. Cytoplasmic lncRNAs can act as decoys to sequester RNA binding proteins or miRNAs (sponges or ceRNAs) or interfere with post-translational modifier proteins (Chen, 2016; Schmitt and Chang, 2016).

Over the last decades, it has become clear that MYC is not only regulated by and regulates many protein-coding genes, but this extensive network also includes the family of ncRNAs. The overall aim of this review was to present an overview of the intricate crosstalk between ncRNAs and MYC. We first focus on ncRNAs acting upstream of MYC by regulating its transcription, translation, and activity. In addition, we focus on ncRNAs acting downstream of MYC and pinpoint their contributions to crucial hallmarks of cancer.

## 2. ncRNAs regulating MYC

### 2.1. miRNAs regulating MYC

In total, twenty-five miRNAs belonging to twenty different seed families have been described to directly regulate MYC (Fig. 1). Most of the miRNAs bind to the MYC transcript in a canonical fashion, that is, with

#### Abbreviations

AGO2, Argonaute 2; Akt, AKT serine/threonine kinase; AMBRA1, activating molecule in Beclin-1-regulated autophagy; AMPK, AMP-activated kinase; ARE, A+U-rich element; ATP, adenosine triphosphate; AUF1, A + U-rich element RNA-binding protein; BAD, BCL2-associated agonist of cell death; BCYRN1, brain cytoplasmic RNA 1; CASC11, cancer susceptibility candidate 11; CCAT, colon cancer-associated transcript; CCN, cyclin; CDC, cell division cycle; CDK, cyclin-dependent kinase; CDKN, cyclin-dependent kinase inhibitor; ceRNA, competing endogenous RNA; CIP2A, cancerous inhibitor of protein phosphatase 2A; CNBP, cellular nucleic acid-binding protein; CONCR, cohesion regulator noncoding RNA; CTCF, CCCTC-binding factor; CTGF, connective tissue growth factor; DANCR, differentiation antagonizing non-protein-coding RNA; DDX11, DEAD/H-box helicase 11; DNMT3a, DNA methyltransferase 3a; EMT, epithelial–mesenchymal transition; EPIC1, epigenetically induced lncRNA 1; EZH2, enhancer of zeste 2 polycomb repressive complex 2; Fbxw7, F-box and WD repeat-containing protein 7; FILNC1, FoxO-induced lncRNA 1; G6PD, glucose-6-phosphate dehydrogenase; GADD45A, growth arrest and DNA damage-inducible alpha; GHET1, gastric carcinoma high expressed transcript 1; GIT2, G-protein-coupled receptor kinase interactor 2; GLS, glutaminase; GLUT, glucose transporter member; GSK3 $\beta$ , glycogen synthase kinase 3 beta; HDAC3, histone deacetylase 3; HIF1 $\alpha$ , hypoxia-inducible factor 1 $\alpha$ ; HK2, hexokinase 2; HMGA2, high-mobility group AT-hook 2; hnRNP, heterogeneous nuclear ribonucleoprotein; HOTAIR, homeobox transcript antisense intergenic RNA; HuR, RNA-binding protein human antigen R; IDH1, isocitrate dehydrogenase 1; IGF2BP, insulin-like growth factor 2 mRNA-binding protein; IL-6, interleukin 6; IRES, internal ribosome entry segment; JAK, Janus kinase; LAST, lncRNA-assisted stabilization of transcripts; LDHA, lactate dehydrogenase A; LIFR, leukemia inhibitory factor receptor; Lin28B, Lin28 homolog B; Linc-RoR, lincRNA regulator of reprogramming; lncRNA, long noncoding RNA; MAX, MYC-associated protein X; MIF, MYC inhibitory factor; MINCR, MYC-induced long noncoding RNA; miRNA, microRNA; MMP, metalloproteinase; mTOR, mechanistic target of rapamycin kinase; MYCBP, MYC-binding protein; MYC, myelocytomatosis viral oncogene homolog; MYU, MYC-induced lncRNA; ncRNA, noncoding RNA; NEAT1, nuclear-enriched abundant transcript 1; NF $\kappa$ B, nuclear factor kappa B; OGT, O-GlcNAc transferase; PCAT-1, prostate cancer-associated ncRNA transcript 1; PCGEM1, prostate cancer gene expression marker 1; PDH, pyruvate dehydrogenase; PDIA3P, protein disulfide isomerase family A member 3 pseudogene 1; PDK, pyruvate dehydrogenase kinase; PFK, phosphofructokinase; PI3K, phosphatidylinositol-4,5-bisphosphate 3 kinase; PKM2, pyruvate kinase M2; PP2A, protein phosphatase 2A; PPP, pentose phosphate pathway; PTEN, phosphatase and tensin homolog; Puma, p53 upregulated modulator of apoptosis; PVT1, plasmacytoma variant translocation 1; RB1, RB transcriptional corepressor 1; RISC, RNA-induced silencing complex; ROCK, Rho-associated coiled-coil-containing protein kinase; SMAD, mothers against decapentaplegic homolog; SNAI, snail family transcriptional repressor 1/2; SNHG, small nucleolar RNA host gene; SOCS5, suppressor of cytokine signaling 5; SPOP, speckle-type POZ; STAT3, signal transducer and activator of transcription 3; SUFU, suppressor of fused homolog; TCA, tricarboxylic acid cycle; TCF7L2, transcription factor 7 like 2; TFAP4, transcription factor AP-4; TFPD2, transcription factor Dp-2; TGFBR2, TGF- $\beta$  receptor type II; TGF- $\beta$ , transforming growth factor- $\beta$ ; THBS, thrombospondin-1; THOR, testis-associated highly conserved oncogenic long noncoding RNA; TOB2, transducer of ERBBs; TUSC2, tumor suppressor candidate 2; UBE3C, ubiquitin protein ligase E3C; USP28, ubiquitin-specific peptidase 28; VASH2, vasohibin-2; VEGF, vascular endothelial growth factor; Wif1, Wnt inhibitory factor 1; YAP, yes-associated protein; ZEB, zinc finger E-box-binding homeobox; ZNF281, zinc finger protein 281.

so-called seed-containing binding sites in the 3'UTR. Binding of let-7b/c-5p is enhanced by adjacent binding of the RNA-binding protein HuR, which makes the miRNA binding site accessible (Kim *et al.*, 2009). One of the two miR-24-3p binding sites is seed-containing, while the other less-efficient site is 'seedless' and has extensive complementarity at the 3'-end of the miRNA (Lal *et al.*, 2009). MiR-17-5p was shown to bind to the 5' UTR of the MYC mRNA (Liu *et al.*, 2016), while miR-184-3p (Zhen *et al.*, 2013), miR-185-3p (Liao and Liu, 2011), miR-320b-3p (Wang *et al.*, 2015), and miR-744-5p (Lin *et al.*, 2014) bind to the MYC ORF.

Next to regulating MYC in a direct fashion, miR-24-3p can also influence MYC protein levels indirectly by targeting OGT. OGT can *O*-GlcNAcylate the MYC protein and thereby increase its stability (Liu *et al.*, 2017). A second miRNA that can act indirectly on MYC is miR-375-3p, which targets CIP2A. CIP2A prevents phosphorylation of Ser62 on MYC by PP2A and thereby prevents degradation of MYC (Jung *et al.*, 2013). So, miR-24-3p and miR-375-3p can downregulate MYC protein levels indirectly by targeting OGT and CIP2A, respectively.

Many of the miRNAs that can directly downregulate MYC by binding to the MYC mRNA, show reduced levels in cancer. The decreased expression of these miRNAs can thus contribute to the high levels of MYC as commonly observed in cancer. Examples are the let-7-5p family, miR-148a-5p, miR-331-3p, and miR-363-3p, which are downregulated in Burkitt lymphoma compared to normal lymph nodes (Bueno *et al.*, 2011). A well-known exception is miR-17-5p, which is part of the oncogenic miR-17~92 cluster that


is often upregulated in MYC-driven cancers. As too high MYC levels are potentially dangerous for cancer cells, targeting of MYC by miR-17-5p may be a means to maintain optimal MYC levels and sustain continuous tumor growth (Liu *et al.*, 2016).

## 2.2. lncRNAs regulating MYC


Expression of MYC is controlled at the level of transcription, translation, and protein stability. Several lncRNAs have been demonstrated to play a role in these regulatory processes. Here, we describe the lncRNAs with a well-characterized role in MYC regulation (Fig. 2).

### 2.2.1. lncRNAs regulating MYC transcription in cis

Besides the MYC gene, the 8q24 region harbors several noncoding genes that can regulate MYC transcription. CCAT1-L transcript variant of the CCAT1 gene and CCAT2 are specifically expressed in colorectal cancer (Ling *et al.*, 2013; Xiang *et al.*, 2014). CCAT1-L is a nuclear lncRNA that accumulates in distinct nuclear foci near its site of transcription. Knockdown of CCAT1-L reduced, while overexpression enhanced transcription of MYC in *cis*. This regulatory effect on MYC was attributed to the spatial proximity of the CCAT1-L locus with the MYC promoter. Indeed, reduced chromatin loop formation between the CCAT1-L and MYC loci was observed upon knockdown of CCAT1-L transcription. The loop formation was dependent on interaction of CCAT1-L with CTCF, which enhanced binding of CTCF to the MYC locus (Xiang *et al.*, 2014). CCAT2 regulates MYC by



**Fig. 1.** miRNA-binding sites on the MYC mRNA. Schematic representation of the MYC mRNA with the binding sites of the MYC-regulating miRNAs indicated. Only miRNAs for which binding to the mRNA was proven at least by reporter assay have been implemented in the figure. The miRNAs let-7a/b/c/e/f-5p and miR-98-5p of the let-7 family (Bueno *et al.*, 2011; Kim *et al.*, 2009), miR-24-3p (Lal *et al.*, 2009), miR-33b-5p (Takwi *et al.*, 2012), miR-34a/c-5p (Christoffersen *et al.*, 2010; Kong *et al.*, 2008), miR-145-5p (Sachdeva *et al.*, 2009), miR-135b-5p (Liu *et al.*, 2014), miR-148a-5p (Han *et al.*, 2013), miR-182a-5p (Huang *et al.*, 2017), miR-331-3p (Bueno *et al.*, 2011), miR-363-3p (Bueno *et al.*, 2011), miR-449c-5p (Miao *et al.*, 2013), miR-451-5p (Li *et al.*, 2011), miR-494-3p (Zhang *et al.*, 2012b), and miR-1294-5p (Liu *et al.*, 2015a) target the MYC mRNA by binding to its 3' UTR, while miR-17-5p binds to the 5' UTR (Liu *et al.*, 2016) and miR-184-3p (Zhen *et al.*, 2013), miR-185-3p (Liao and Liu, 2011), miR-320b-3p (Wang *et al.*, 2015), and miR-744-5p (Lin *et al.*, 2014) bind to the MYC ORF.



**Fig. 2.** lncRNAs regulating MYC at the DNA, mRNA, or protein levels. lncRNAs and their interaction partners involved in regulation of MYC transcription, translation, stability, and functionality at protein level are indicated. The genomic region around MYC and the MYC mRNA (central thick and curved gray line) are not drawn to scale. lncRNAs are indicated by curved lines and proteins by ellipses. lncRNAs highlighted in blue indicate that they stimulate and lncRNA highlighted in yellow indicate that they repress MYC transcription, translation, stability, or functionality, and the arrows indicate stimulating or repressing effects on MYC.

enhancing the activity of TCF7L2, a transcription factor for MYC (Ling *et al.*, 2013). Thus, both CCAT1-L and CCAT2 positively regulate MYC transcription.

Interaction between an enhancer region downstream the first transcriptional start site of PVT1 and the PVT1 promoter itself has tumor suppressor activity by reducing MYC transcription (Cho *et al.*, 2018). Silencing of the PVT1 promoter increased MYC expression independent of the PVT1 transcript itself. The underlying mechanism has been identified as a

competition between the PVT1 promoter and the MYC promoter for interaction with the intragenic enhancer region in the PVT1 locus. Under normal conditions, these enhancers preferentially bind to the PVT1 promoter. Silencing of the PVT1 promoter allowed interaction of enhancers with the MYC promoter, leading to increased MYC transcription. Importantly, this effect is restricted to cells where MYC forms chromatin loops with PVT1, for example, breast cancer, as opposed to colorectal cancer or



cervical carcinoma cells where MYC loops to the CCAT1 enhancer.

The levels of three partially overlapping lncRNA transcripts antisense to the 3' distal region of MYC, NAT6531, NAT6538, and NAT7281, are regulated by histone H3 acetylation in prostate cancer cells. Under normal conditions, NAT6531 is expressed and processed by DICER into several short RNAs, which have a repressive effect on MYC transcription, possibly by binding to the MYC promoter and intron 1 through partial sequence complementarity. Partial inhibition of histone deacetylation shifts transcription from NAT6531 to NAT6538, and this releases the block on MYC transcription. Strong inhibition of histone deacetylation results in transcription of the longer NAT7281, which strongly represses MYC transcription (Napoli *et al.*, 2017).

### 2.2.2. LncRNAs controlling MYC mRNA stability and translation

IGF2BPs enhance mRNA stability and promote translation by binding to the MYC mRNA (Huang *et al.*, 2018). A number of cell type-specific lncRNAs have been identified that modulate this interaction. Interaction of IGF2BP1 with lncRNA GHET1 in gastric cancer and THOR in renal and skin cancer increased MYC mRNA and protein levels (Liu *et al.*, 2018; Yang *et al.*, 2014; Ye *et al.*, 2018). In contrast, binding of the skeletal muscle-specific lncRNA lncMyoD to IGF2BP2 decreased MYC mRNA levels by preventing binding of IGF2BP2 to MYC mRNA (Gong *et al.*, 2015).

Binding of AUF1 to an ARE site in the 3'UTR of the MYC transcript can both positively and negatively affect MYC levels, depending on the cell-type. In normal kidney cells, FILNC1 acts as a decoy for AUF1 preventing binding of AUF1 to the MYC mRNA, thereby resulting in low MYC protein levels. In renal cancer, FILNC1 is downregulated, resulting in an AUF1-dependent increase in MYC protein levels (Xiao *et al.*, 2017). In breast and colon cancers, binding of linc-RoR to AUF1 inhibits binding of AUF1 to MYC mRNA and thereby increases MYC levels (Huang *et al.*, 2015). It is currently unclear why sequestering of AUF1 has opposite effects on MYC levels in these different cell types. In addition, linc-RoR facilitates binding of RNA binding protein hnRNP-I to MYC mRNA and this also enhances MYC protein levels.

MYC can be translated using an IRES in case the regular cap-dependent translation is compromised. This requires binding of the IRES trans-acting factors

PSF and p54nrb (Cobbold *et al.*, 2008). These factors are sequestered by lncRNA NEAT1 to the paraspeckles. In HeLa cells, depletion of NEAT1 during nucleolar stress released PSF and p54nrb from paraspeckles and allowed IRES-dependent translation of MYC (Shen *et al.*, 2017).

LncRNAs can also stimulate MYC mRNA translation by competing with MYC-regulating miRNAs. This has been shown for PCAT-1, which competes with miR-34a-5p for interaction with its binding site in the 3' UTR of the MYC mRNA (Prensner *et al.*, 2011, 2014). The effect of PCAT-1 can be antagonized by miR-3667-3p, which targets PCAT-1.

### 2.2.3. LncRNAs affecting MYC protein stability and activity

The stability of MYC protein can be increased by two lncRNAs that both prevent its degradation, but via distinct mechanisms. In contrast to the tumor-suppressive role of the PVT1 promoter, the PVT1 transcript can act as an oncogene. PVT1 stabilizes the MYC protein by preventing phosphorylation of threonine 58, which is a signal for its degradation (Tseng *et al.*, 2014). LINC01638 prevents MYC protein degradation by preventing binding of E3 ubiquitin ligase adapter SPOP to MYC (Luo *et al.*, 2018).

Three lncRNAs modulate interaction of MYC with (subsets of) its target genes by directly binding to MYC. PCGEM1 is a prostate-specific lncRNA, which together with MYC co-occupies the promoter regions of several metabolic genes documented to be MYC targets. Knockdown of PCGEM1 reduced recruitment of MYC to the promoters of these PCGEM1-dependent metabolic genes without affecting MYC protein levels (Hung *et al.*, 2014). Thus, PCGEM1 affects the metabolic state of cancer cells by enhancing MYC occupancy at the promoters of several metabolic genes. LncRNA PDIA3P regulates the metabolic state of multiple myeloma cells via induction of G6PD, an enzyme crucial for promoting the PPP flux (Yang *et al.*, 2018). This effect is achieved by interaction of PDIA3P with MYC and promoting MYC binding to the G6PD promoter. Together with MYC, lncRNA EPIC1 co-occupies the promoters of > 97% of EPIC1-regulated genes involved in cell cycle progression, and thereby regulates transcriptional activity of these genes in breast cancer cells (Wang *et al.*, 2018).

From the studies presented here, lncRNAs emerge as important regulators of MYC expression and activity, either directly or indirectly by interacting with proteins. Often, these lncRNAs are deregulated in cancer and promote high MYC levels and activity. Since

expression of lncRNAs is highly cell type specific, many of the lncRNA-MYC interactions are restricted to certain tissues. Future studies will likely broaden the repertoire of lncRNAs regulating MYC and improve the understanding of the underlying mechanisms in normal and cancer cells.

### 2.3. Feedback loops on MYC

Next to the more straightforward regulation of MYC by ncRNAs as described above, more complex feedback loops between MYC and MYC-regulating ncRNAs have been identified. These include feedback loops that involve MYC-regulated miRNAs, as well as MYC-regulated lncRNAs that act as sponges for MYC-regulating miRNAs.

#### 2.3.1. Feedback loops involving MYC-regulated miRNAs

Several miRNAs that regulate MYC can be induced or repressed by MYC as well, resulting in the formation of feedback loops. Examples of this are the feedback loops between MYC and MYC-induced miR-7-5p (Capizzi *et al.*, 2017; Chou *et al.*, 2010), miR-17-5p (Liu *et al.*, 2016), and miR-185-3p (Liao and Liu, 2011). For miR-7-5p, a positive feedback loop is formed via the miR-7-5p target AMBRA1, which promotes dephosphorylation of Ser62 on MYC upon binding to PP2A. This leads to stimulation of proteosomal degradation of MYC (Capizzi *et al.*, 2017; Cianfanelli *et al.*, 2015). In this way, miR-7-5p indirectly enhances MYC protein stability and promotes its own MYC-mediated transcription. MiR-17-5p and miR-185-3p were shown to directly target MYC mRNA resulting in a negative feedback loop (Liao and Liu, 2011; Liu *et al.*, 2016).

Positive feedback loops that result in sustaining high MYC expression also involve MYC-repressed miRNAs. Let-7a-5p, miR-34a-5p, miR-148a-5p, miR-363-3p, and miR-451-5p are examples of MYC-repressed miRNAs that can directly repress MYC translation (Bommer *et al.*, 2007; Bueno *et al.*, 2011; Christoffersen *et al.*, 2010; Ding *et al.*, 2018; Han *et al.*, 2013; Sampson *et al.*, 2007). Besides MYC, miR-363-3p also targets USP28, a de-ubiquitinase involved in MYC stabilization (Han *et al.*, 2013). MiR-22 forms a feedback loop with MYC by targeting the MYCBP transcript, which encodes a positive regulator of MYC transcriptional activity (Xiong *et al.*, 2010). In hepatocellular carcinoma, repression of liver-specific miR-122-5p results in derepression of the miR-122 targets E2F1 and its interaction partner TFDP2 (Wang *et al.*, 2014).

Both targets are involved in the induction of MYC transcription, creating another feedback loop. MiR-200b-3p participates in a feedback loop that involves MYC protein stability by targeting Akt2 mRNA (Lv *et al.*, 2017). Akt2 represses the activity of GSK3 $\beta$ , an enzyme that destabilizes the MYC protein by phosphorylation of threonine residue 58. Thus, by repressing miR-200b-3p, MYC ensures inhibition of GSK3 $\beta$ , thereby stimulating its own stability. In contrast, MYC-repressed miR-30a-5p is involved in a negative feedback loop by targeting UBE3C mRNA, a protein that can ubiquitinate MYC for proteosomal degradation (Chang *et al.*, 2008; Xiong *et al.*, 2016).

#### 2.3.2. Feedback loops involving MYC-regulated lncRNAs acting as miRNA sponges

The functions of several MYC-regulating miRNAs can be antagonized by MYC-regulated lncRNAs, which act as sponges. By sequestering those miRNAs, the following MYC-induced lncRNAs ensure high MYC levels and create a positive feedback loop on MYC: CCAT1-S, the short isoform of CCAT1-L (let-7a/b/c/e-5p) (Deng *et al.*, 2015), DANCR (miR-33b-5p) (Ma *et al.*, 2018), H19 (let-7a/b-5p) (Peng *et al.*, 2017; Zhou *et al.*, 2017), linc00176 (miR-185-5p) (Tran *et al.*, 2017), and SNHG3 (miR-182a-5p) (Huang *et al.*, 2017). Another lncRNA that ensures high MYC levels by sequestering miRNAs of the let-7-5p family without being regulated by MYC is lncRNA CCR492 (Maldotti *et al.*, 2016). In contrast, the MYC-induced lncRNA-MIF reduces MYC levels and creates a negative feedback loop by sequestering miR-586 (Zhang *et al.*, 2016a). This miRNA targets the mRNA encoding E3 ubiquitin ligase Fbxw7, which stimulates MYC degradation. Although this does not seem beneficial for cancer cells, it might be that with the overall broad effects of MYC, lncRNA-MIF is an additional factor in fine-tuning the most optimal MYC levels.

### 3. MYC-regulated ncRNAs involved in five important hallmarks of cancer

The C13ORF25 RNA also known as the primary transcript of the oncogenic miR-17~92 cluster was identified as being MYC-induced in 2005 (He *et al.*, 2005; O'Donnell *et al.*, 2005). The induction of this cluster is achieved by binding of MYC together with E2F1-3 transcription factors to its promoter (Sylvestre *et al.*, 2007; Woods *et al.*, 2007). The miR-17~92 cluster has two paralogs: the miR-106a~363 cluster and the miR-106b~25 cluster (Tanzer and Stadler, 2004). The miR-106b~25 cluster is also regulated by E2F1 in

combination with MYC (Petrocca *et al.*, 2008). In 2008, multiple MYC-repressed miRNAs were identified using a human and a mouse B-cell lymphoma model (Chang *et al.*, 2008). MYC represses expression of specific pri-miRNAs by binding to their promoter regions and recruitment of HDAC3 (miR-15a/16 cluster) (Zhang *et al.*, 2012a), HDAC3 and EZH2 (miR-26a, miR-19, and miR-129) (Han *et al.*, 2016; Zhang *et al.*, 2012b; Zhao *et al.*, 2013), or DNMT3a (miR-34a) (Craig *et al.*, 2011). Repression of the members of the let-7 family by MYC is regulated post-transcriptionally by the MYC-induced RNA binding protein Lin28B (Chang *et al.*, 2009).

One of the first identified MYC-regulated lncRNAs is CCAT1. While the CCAT1-L transcript variant is specifically overexpressed in colorectal cancer, the CCAT1-S variant is upregulated in many other cancers, including gastric carcinoma and colon cancer (He *et al.*, 2014; Yang *et al.*, 2013a). By binding to the E-box element in the promoter region of *CCAT1*, MYC induces expression of CCAT1-S. As the short transcript variant is most likely formed by 3' processing of the long variant, MYC probably induces expression of CCAT1-L, but this has not been proven. Besides CCAT1 and CCAT2, six other colorectal cancer-associated MYC-regulated lncRNAs (MYCLOs/CCAT3-8) have been identified (Kim *et al.*, 2015a,b). Three of them are MYC-induced, and the other three are MYC-repressed. In the last five years, many more MYC-regulated lncRNAs have been identified although for many their function has not yet been identified (Hart *et al.*, 2014; Winkle *et al.*, 2015).

Below, we describe in more detail the MYC-regulated miRNAs (Table 1 and Fig. 3) and lncRNAs (Table 2 and Fig. 4) with a clear role in five main hallmarks of cancer, that is, cell cycle progression, apoptosis, metabolism, angiogenesis, and metastasis.

### 3.1. Cell cycle progression

Nineteen MYC-induced ncRNAs have a role in cell cycle progression. LncRNA-assisted stabilization of transcripts (LAST) stimulates CCND1 expression by stabilizing CCND1 mRNA together with CNBP (Cao *et al.*, 2017). MiR-378a-3p ensures CCND1 expression by targeting mRNA encoding TOB2, which is a repressor of CCND1 expression (Feng *et al.*, 2011). CASC11 (CARLo-7) promotes CCND1 transcription by stabilizing the hnRNP-K mRNA, which leads to an hnRNP-K-dependent enhanced nuclear accumulation of  $\beta$ -catenin (Zhang *et al.*, 2016b). This leads to activation of WNT/ $\beta$ -catenin signaling, and the subsequent induction of CCND1 transcription. The

MYC-induced lncRNA MY (VSP9D1-AS1) associates with hnRNP-K and stimulates CDK6 mRNA translation by competing with miR-16-5p for binding to CDK6 mRNA (Kawasaki *et al.*, 2016). CDKN2B transcription is repressed by lncRNA CCAT-6 upon binding of this lncRNA to hnRNP-K (Kim *et al.*, 2015b). All three lncRNAs interacting with hnRNP-K (CASC11, MYU, and CCAT-6) have been shown to stimulate cell cycle progression in colon cancer. The four lncRNAs HOTAIR, MYCLO-1, CCAT1-S, and DANCER all repress CDKN1A transcription (Kim *et al.*, 2014, 2015b; Liu *et al.*, 2013; Lu *et al.*, 2018; Ma *et al.*, 2014). HOTAIR represses CDKN1A transcription by recruiting EZH2 and inducing epigenetic changes, while MYCLO-1 is assisted by HuR to repress the transcription of CDKN1A. The mechanisms by which CCAT1-S and DANCER repress CDKN1A transcription are not yet known. Members of the miR-17-5p seed family have been strongly implicated in stimulation of cell cycle progression by targeting CDKN1A (Ivanovska *et al.*, 2008; Kim *et al.*, 2009; Trompeter *et al.*, 2011). Conversely, the same seed family represses cell cycle progression by targeting CCND1/2 transcripts (Trompeter *et al.*, 2011; Yu *et al.*, 2008) and E2F1-3 transcripts (He *et al.*, 2005; Luan *et al.*, 2018; O'Donnell *et al.*, 2005; Trompeter *et al.*, 2011). This is consistent with the cell type-specific roles as oncomiR as well as tumor suppressor miR that have been observed for individual members of the miR-17-5p seed family (He *et al.*, 2005; O'Donnell *et al.*, 2005). The MYC-induced lncRNA CONCR plays a role during S-phase and is required for cell division by regulating the activity of helicase DDX11, which is involved in DNA replication and sister chromatid cohesion (Marchese *et al.*, 2016). The MYC-induced lncRNA MINCR promotes MYC-mediated transcription of a selected set of cell cycle genes (Doose *et al.*, 2015), although there is some debate about whether this lncRNA is a direct MYC-induced lncRNA or not (Doose *et al.*, 2015, 2016; Hart *et al.*, 2016). Besides, MINCR functions as a sponge for miR-26a-5p to stimulate cell cycle progression (Wang *et al.*, 2016).

Eleven MYC-repressed ncRNAs inhibit cell cycle progression, while one MYC-repressed miRNA stimulates cell cycle progression. The CCND1-3 and CCNE1-2 transcripts are targeted by let-7b-5p (Johnson *et al.*, 2007), the miR-15-5p seed family (Bonci *et al.*, 2008; Wang *et al.*, 2009; Xu *et al.*, 2009), miR-26a/b-5p (Kota *et al.*, 2009; Zhu *et al.*, 2012), and miR-34a-5p (He *et al.*, 2007; Pok *et al.*, 2013; Sun *et al.*, 2008). In addition, these miRNAs and miR-29a-c-3p target CDK4/6 transcripts (He *et al.*,



**Table 1.** MYC-regulated miRNAs with a function related to important hallmarks of cancer.

	Proven target gene(s) <sup>a</sup>	Cellular processes <sup>b</sup>
MYC-induced		
miR-9-5p	<i>CDH1, LIFR, SOCS5</i>	Angiogenesis, metastasis
miR-17-5p	<i>BIM, CCND1/2, E2F1-3, CDKN1A, PTEN, TGFBR, VEGF</i>	Cell cycle progression, angiogenesis, apoptosis, metastasis
miR-18-5p	<i>CTGF, SMAD4</i>	Angiogenesis, metastasis
miR-19-3p	<i>AMPK, BIM, PP2A, PTEN, THBS1</i>	Apoptosis, angiogenesis, metabolism
miR-25-3p	<i>BIM, USP28</i>	Cell cycle progression
miR-378-3p	<i>TOB2</i>	Cell cycle progression
miR-378a-5p	<i>SUFU, TUSC1</i>	Angiogenesis
MYC-repressed		
let-7-5p	<i>CCND2, CDC25, CDC34, CDK6, HMGA2</i>	Cell cycle progression, metastasis
miR-15-5p	<i>AP4, BCL2, CCND1/E1, CDK6, E2F3, GLUT3, SMAD3, VEGF</i>	Cell cycle progression, apoptosis, metabolism, angiogenesis
miR-23-3p	<i>GLS, LDHA/B, SMAD3-5</i>	Metabolism, metastasis
miR-26-5p	<i>CCND2/E1-2, CDK6, E2F3, EZH2, IL-6, MCL1, PDHX, PTEN, RB1</i>	Cell cycle progression, apoptosis, metabolism, metastasis
miR-29-3p	<i>AKT3, CDK6, MCL1, MMPP2, VASH2, VEGF</i>	Cell cycle progression, apoptosis, angiogenesis, metastasis
miR-30-5p	<i>LDHA, UBE3C</i>	Metabolism, MYC regulation
miR-34-5p	<i>BCL2, CCND1/E2, CDK4, CDK6, SNAI1, ZNF281</i>	Cell cycle progression, apoptosis, metastasis
miR-122-5p	<i>BCL2L2, E2F1, TFDP2</i>	Apoptosis
miR-129-5p	<i>PDK4</i>	Metabolism
miR-200-3p	<i>AKT2, CDKN1B, CTNNB1, GIT2, ROCK2, VEGF, ZEB-1, ZEB-2</i>	Cell cycle progression, angiogenesis, metastasis


<sup>a</sup>Not all members of the seed families target the proven target genes. <sup>b</sup>Not all target genes mentioned in column two are involved in the cellular processes mentioned here.

2007; Johnson *et al.*, 2007; Kawasaki *et al.*, 2016; Sun *et al.*, 2008; Xu *et al.*, 2009; Zhao *et al.*, 2010; Zhu *et al.*, 2012). The RB1 transcript is targeted by miR-26a-5p (López-Urrutia *et al.*, 2017), and the E2F3 transcript is targeted by miR-195-5p, a member of the miR-15-5p seed family (Xu *et al.*, 2009). Let-7b-5p targets the CDC25 transcript, which results in reactivation of CDKs to enable cell cycle progression (Hoffmann, 2000). Let-7b-5p also targets CDC34, which is an ubiquitin-conjugating enzyme that is involved in the degradation of Wee1, an inhibitor of CDK1 (Legesse-Miller *et al.*, 2009). The miR-15-5p seed family members target TFAP4, which results in repression of CDKN1A and CDKN2A transcription and reduced p21 and p16 levels (Jackstadt *et al.*, 2013a). MiR-200b-3p targets the CDKN1B transcript, leading to reduced p27 levels and stimulation of cell cycle progression (Fu *et al.*, 2014). So, it seems not beneficial for cancer cells that MYC represses miR-200b-3p. MYCLo-4 and MYCLo-6 both block G2 to M phase progression by stimulating growth arrest and GADD45A expression, a critical regulator of G2 arrest (Kim *et al.*, 2015a). MYCLo-5 is involved in controlling S to G2 phase progression, but the exact mechanism is not yet known.

### 3.2. Apoptosis

Seven MYC-induced and eight MYC-repressed ncRNAs influence the balance between pro- and anti-apoptotic factors. The MYC-induced miR-19a/b-3p, miR-20a-5p, miR-25-3p, and miR-92a-3p prevent apoptosis by targeting the BIM transcript (Mogilyansky and Rigoutsos, 2013; Petrocca *et al.*, 2008; Xiao *et al.*, 2008). In addition, miR-19a/b-3p target transcripts of the PTEN, PP2A, and AMPK genes, resulting in decreased levels of the downstream pro-apoptotic proteins BAD, Puma, and Noxa (Mavrakis *et al.*, 2010; Mu *et al.*, 2009; Olive *et al.*, 2009). CCAT1-S was shown to upregulate the expression of Livin, which is a member of the inhibitor of apoptosis protein family that can interact with caspases to prevent apoptosis (Chen *et al.*, 2017).

Many of the MYC-repressed miRNAs directly target anti-apoptotic factors; for example, miR-15a/16-5p and miR-34a-5p target the BCL2 transcript (Bommer *et al.*, 2007; Bonci *et al.*, 2008; Cimmino *et al.*, 2005), miR-122-5p targets the BCL2L2 transcript (Lin *et al.*, 2008; Wang *et al.*, 2014), and miR-26b-5p and miR-29b-3p target the MCL1 transcript (Jiang *et al.*, 2015; Mott *et al.*, 2007). Moreover, by targeting the IL-6 transcript, miR-26a-5p represses STAT3 signaling,



**Fig. 3.** MYC-regulated miRNAs involved in five important hallmarks of cancer. For each hallmark, the MYC-regulated miRNAs and their protein targets involved in stimulation (green) or repression (red) of the respective hallmark are indicated.

**Table 2.** MYC-regulated lncRNAs with a function related to important hallmarks of cancer.

	Proven target gene(s)	Cellular processes <sup>a</sup>
MYC-induced		
BCYRN1	↑ <i>MMP2/9/13, VEGF</i>	Angiogenesis, metastasis
CASC11	↑ <i>HNRNP</i>	Cell cycle progression
	↓ <i>WIF1</i>	Metastasis
CCAT1-S	↑ <i>BIRC7</i>	Apoptosis
	↓ <i>CDKN1A, I</i>	Cell cycle progression, metastasis
	et-7a/b/c/e-5p, miR-148a-3p	
CCAT6	↓ <i>CDKN2B</i>	Cell cycle progression
CONCR	↑ <i>DDX11</i>	Cell cycle progression
DANCR	↓ <i>CDKN1A, miR-33b-5p</i>	Cell cycle progression
H19	↓ <i>CDH1, let-7a/b-5p, miR-29a-3p, miR-106a-5p, miR-200a-c-3p</i>	Cell cycle progression, metabolism, angiogenesis, metastasis
HOTAIR	↓ <i>CDKN1A, WIF1, miR-34a-5p</i>	Cell cycle progression, metastasis
LAST	↑ <i>CCND1</i>	Cell cycle progression
Linc00176	↓ miR-9-5p, miR-185-5p	Cell cycle progression
LncRNA-MIF	↓ miR-586-5p	Metabolism
MINCR	↓ miR-26a-5p	Cell cycle progression, apoptosis, metastasis
MYCLO-1	↓ <i>CDKN1A</i>	Cell cycle progression
MYU	↑ <i>CDK6</i>	Cell cycle progression
SINGH12	↑ <i>MMP13</i>	Metastasis
MYC-repressed		
IDH1-AS1	↑ <i>IDH1</i>	Metabolism
MYCLO-4	↑ <i>GADD45A</i>	Cell cycle progression
MYCLO-5	<i>Unknown</i>	Cell cycle progression
MYCLO-6	↑ <i>GADD45A</i>	Cell cycle progression


↑ indicates induced/stabilized/activated by the lncRNA, and ↓ indicates being repressed by the lncRNA. <sup>a</sup>Not all proven target genes mentioned in column two are involved in the cellular processes mentioned here.

which results in reduced Bcl2 and Mcl1 expression levels (Yang *et al.*, 2013b). The effects of miR-26a-5p can be antagonized by MYC-induced MINCR, which functions as a sponge for this miRNA and prevent apoptosis (Wang *et al.*, 2016).

### 3.3. Metabolism

Three MYC-induced and eight MYC-repressed ncRNAs are involved in the regulation of aerobic glycolysis, a feature of cancer cells. By targeting PTEN and PP2K transcripts, miR-19a/b-3p enhances PI3K activity (Mavrakis *et al.*, 2010; Mu *et al.*, 2009; Olive *et al.*, 2009). This results in phosphorylation of Akt by PDK1, which stimulates glycolysis through multiple mechanisms, such as increased expression of several glucose transporters, activation of PFK1/2 (important regulatory enzymes of glycolysis), and mTOR. To further ensure high mTOR activity, miR-19a/b-3p also targets AMPK, an inhibitor of mTOR activity (Bolster *et al.*, 2002; Mavrakis *et al.*, 2010). MiR-106a-5p targets the E2F3 transcript, which results in repression of the glucose metabolism (Luan *et al.*, 2018). This is antagonized by H19, which has been proposed to promote glucose metabolism by acting as a sponge for miR-106a-5p. MIF influences the glycolytic activity by sequestering miR-586, thereby preventing expression of MYC target genes involved in glycolysis, that is, *GLUT1*, *LDHA*, *PKM2*, and *HK2* (Zhang *et al.*, 2016a).

miRNAs repressed by MYC typically inhibit high metabolic activity. The initial uptake of glucose is regulated by miR-195-5p, which targets *GLUT3* (Fei *et al.*, 2012). MiR-23a/b-3p targets the mRNA



**Fig. 4.** MYC-regulated lncRNAs involved in five important hallmarks of cancer. For each hallmark, the lncRNAs that are promoting or inhibiting are indicated. Cell survival represents the opposite of apoptosis in this figure. LncRNAs highlighted in blue are MYC-induced, lncRNAs highlighted in yellow are MYC-repressed, and lncRNAs in italic function as sponges for miRNAs.

encoding GLS, which converts glutamine to glutamate and thereby contributes to production of ATP (Gao *et al.*, 2009). In addition, miR-23a-3p targets LDH subunits A and B (LDHA/LDHB), which convert the glycolytic end product pyruvate to lactate (Poyakkara *et al.*, 2018). Moreover, LDHA is also targeted by miR-30a-5p (Chang *et al.*, 2008; Li *et al.*, 2017a). MiR-26a-5p inhibits PDH activity by targeting PDHX and therefore inhibits the conversion of pyruvate to coenzyme A, an important component of the TCA cycle (Chen *et al.*, 2014a). Instead, pyruvate is converted to lactate, showing an oncogenic role for miR-26a-5p in metabolism. In contrast, miR-129 targets PDK4 mRNA, thereby stimulating PDH activity (Han *et al.*, 2016). MYC-repressed lncRNA IDH1-AS1 stimulates homodimerization of IDH1 by forming a ternary structure with the enzyme, thereby enhancing its activity (Xiang *et al.*, 2018). IDH1 converts isocitrate to  $\alpha$ -ketoglutarate, which is an intermediate in the TCA cycle and can inhibit glycolysis via degradation of HIF1 $\alpha$  under normoxic condition (MacKenzie *et al.*, 2007). By repressing IDH1-AS1, MYC downregulates IDH1 activity and ensures glycolysis.

### 3.4. Angiogenesis

Stimulation of angiogenesis by different mechanisms has been reported for eight MYC-induced ncRNAs, while five MYC-induced and four MYC-repressed miRNAs inhibit angiogenesis by targeting pro-angiogenic factors. Angiogenesis is enhanced by repression of the TGF- $\beta$  signaling pathway. MiR-17-5p and miR-20a-5p target the TGFBR2 transcript, while miR-18a-5p targets the downstream effector SMAD4 (Dews *et al.*, 2010). Besides, several inhibitors of angiogenesis are targeted; miR-19a-3p targets THBS1 (Dews *et al.*, 2010), miR-18a-5p targets CTGF (Ernst *et al.*, 2010; Fox *et al.*, 2013), and miR-378-5p targets TUSC2 and SUFU (Lee *et al.*, 2007). VEGF expression is stimulated directly by lncRNA BCYRN1 (Hu and Lu, 2015; Peng *et al.*, 2018) and indirectly by miR-20a-5p (Wang *et al.*, 2017a). MiR-20a-5p targets PTEN, which leads to increased VEGF levels via activation of the PI3K/Akt pathway. In contrast, VEGF is inhibited by miR-16-5p, miR-17-5p, miR-20a/b-5p, miR-29a-3p, miR-106a/b-5p, and miR-200b-3p (Chen *et al.*, 2014b; Choi *et al.*, 2011; Hua *et al.*, 2006). In this context, miR-200b-3p acts a tumor suppressor in contrast to its oncogenic role in cell cycle regulation. MiR-29b-5p indirectly lowers VEGF levels by targeting the Akt3 transcript (Li *et al.*, 2017b). In melanoma cells, the effect of miR-106a-5p on VEGF expression can be counteracted by H19, which acts as a sponge for this

miRNA (Luan *et al.*, 2018). At first sight, it seems conflictive that both MYC-induced and MYC-repressed miRNAs target VEGF mRNA. However, as angiogenesis is crucial for a wide variety of physiological and pathological processes, VEGF expression has to be tightly regulated. This can be achieved by a combination of several regulatory factors including MYC-induced and MYC-repressed miRNAs, as well as other ncRNAs ensuring optimal VEGF levels under various conditions. MiR-29a-3p also targets the mRNA encoding a second pro-angiogenic factor, VASH2 (Jia *et al.*, 2016). VASH2 inhibition by miR-29a-3p can also be antagonized by H19, which acts as a sponge for miR-29a-3p in glioma microvessels and epithelial cells (Jia *et al.*, 2016).

### 3.5. Metastasis

Ten MYC-induced ncRNAs target metastasis-associated genes. H19 promotes metastasis by recruitment of EZH2 and the subsequent epigenetic suppression of E-cadherin expression (Luo *et al.*, 2013). Loss of E-cadherin allows EMT, an early step in metastasis. MiR-9-5p promotes metastasis by targeting E-cadherin, LIFR, and SOCS5 (Chen *et al.*, 2012; Ma *et al.*, 2010; Zhuang *et al.*, 2012). LIFR inhibits metastasis through the Hippo/YAP pathway, and SOCS5 inhibits endothelial cell migration by inhibiting the JAK/STAT pathway. By interacting with EZH2, CASC11 and HOTAIR epigenetically suppress Wif1 expression and ensure stimulation of metastasis by the Wnt/ $\beta$ -catenin pathway (Ge *et al.*, 2013; Zhang *et al.*, 2016b). As described in the paragraph above, three members of the miR-17-5p seed family target genes involved in the TGF $\beta$  signaling pathway, a crucial pathway also for the induction of metastasis. BCYRN1 stimulates metastasis by inducing the expression of MMP2, MMP9, and MMP13 (Hu and Lu, 2015; Peng *et al.*, 2018). SNHG12 is a second lncRNA that induces the expression of MMP13 (Wang *et al.*, 2017b). In contrast to BCYRN1 that induces MMP13 transcription, SNHG12 enhances MMP13 expression at the post-transcriptional level.

Ten MYC-repressed miRNAs prevent metastasis, while one MYC-repressed miRNA can both induce and prevent metastasis, depending on the cell type. The transcription factors SNAI1/2, ZEB1/2, Twist, and AP4 all repress E-cadherin expression at the transcriptional level (Tania *et al.*, 2014). MiR-34a-5p targets the SNAI1 transcript directly and indirectly by targeting the Krüppel-type transcription factor ZNF281 transcript (Hahn *et al.*, 2013). In addition to being repressed by MYC, miR-34a is also repressed by

HOTAIR upon interaction with EZH2, thereby promoting metastasis in gastric cancer cells (Liu *et al.*, 2015b). Let-7a/b/e-5p repress SNAI1 and SNAI2 expression indirectly by targeting the chromatin remodeling HMGA2 transcript (Lee and Dutta, 2007; Mayr *et al.*, 2007). This is counteracted by CCAT1-S functioning as a sponge for let-7 family members let-7a/b/c/e-5p (Deng *et al.*, 2015). CCAT1-S can also sequester miR-148a-3p in osteosarcoma cells, thereby stimulating invasion and migration via unknown mechanisms (Zhao and Cheng, 2017). ZEB1/2 transcripts are targeted by miR-200a-c-3p (Korpál *et al.*, 2008; Park *et al.*, 2008). The miR-15a-5p seed family targets mRNA encoding AP4, which induces SNAI1 expression (Jackstadt *et al.*, 2013b). The role of miR-26a-5p with respect to metastasis seems to be contradictory. By targeting PTEN mRNA, miR-26a-5p stimulates the Akt/NF $\kappa$ B pathway and thereby induces expression of Twist,  $\beta$ -catenin, and MMP2 in lung cancer (Liu *et al.*, 2012). Increased levels of  $\beta$ -catenin will initiate Wnt signaling, which stimulates metastasis. MMP2 is an essential protease involved in adhesion, invasion, and migration by proteolytic degradation of type IV collagen. In contrast, by targeting IL-6 in hepatocellular carcinoma, miR-26a-5p represses STAT3 signaling and this results in lower MMP2 levels (Yang *et al.*, 2013b). Furthermore, MMP2 is also targeted by miR-29b-3p (Fang *et al.*, 2011). miRNAs that repress metastasis by repressing the downstream SMAD proteins of the TGF $\beta$  signaling pathway are miR-23b-3p (SMAD3-5) (Rogler *et al.*, 2009) and miR-195-5p (SMAD3) (Zhou *et al.*, 2016). MiR-200a-3p targets the mRNA encoding  $\beta$ -catenin in colorectal cancer, thereby repressing metastasis (Yang *et al.*, 2017). Another pathway involved in metastasis by influencing cell motility is the Rho/ROCK signaling pathway, which is repressed by targeting of ROCK2 and GIT2 transcripts by miR-200b/c-3p (Peng *et al.*, 2013; Wong *et al.*, 2015; Zhou *et al.*, 2017). All repressing effects of the miR-200 seed family can be antagonized by H19, which functions as a sponge for these miRNAs (Li *et al.*, 2016; Liang *et al.*, 2015; Yang *et al.*, 2017; Zhou *et al.*, 2017). Besides, MINCR stimulates metastasis by sequestering miR-26a-5p (Wang *et al.*, 2016).

#### 4. Discussion

It is evident that an extensive, multilayered ncRNA network exists around MYC with critical roles for multiple lncRNAs and miRNAs in crucial cellular processes and in tumorigenesis. The picture that we present here is most likely still far from complete, as functions of most of the MYC-regulated ncRNAs are

not known yet (Hart *et al.*, 2014; Robertus *et al.*, 2010; Winkle *et al.*, 2015). It is clear that many miRNAs and lncRNAs regulate MYC and that they can do this via diverse mechanisms at the level of transcription, translation, protein stability, and functionality. This suggests that redundancy is important to ensure optimal MYC levels and thereby cell viability under various conditions, as well as in different cell types. As MYC is involved in many cellular processes in redundant ways, it is remarkable that repression or reintroduction of a single MYC-regulated ncRNA can already show strong effects on MYC-associated phenotypes, as has been shown for many ncRNAs described in this review.

Expression of lncRNAs was shown to be more cell type specific than that of protein-coding genes (Derrien *et al.*, 2012). Also compared to miRNAs, lncRNAs appear to be more cell type-specific. However, this might be biased as there are many more lncRNAs than miRNAs, which increases the chance to find cell type-specific lncRNAs. Based on current knowledge, it seems that the cell type-specific expression of certain lncRNAs can influence the output of MYC in two ways. First, cell type-specific lncRNAs can influence important cellular processes downstream of MYC (Fig. 4). Second, other cell type-specific lncRNAs, like PCGEM1 and PDIA3P, can modulate binding efficiency of MYC to promoters of a specific set of genes. So, these lncRNAs may direct the cell type-specific target gene repertoire of MYC, rather than MYC acting as a general amplifier of expression. Altogether, a picture is emerging that lncRNAs guide cell type-specific effects of MYC.

Although MYC has a central role in tumorigenesis, no effective MYC-specific drugs are being employed in the clinic to date. Given the crucial functions of multiple lncRNAs and miRNAs in the oncogenic MYC network, it is tempting to speculate that targeting of ncRNAs within the MYC network might be an alternative to explore novel anticancer therapies. These ncRNAs can have profound impacts on MYC levels and activity and can also act downstream of MYC enabling cancer cells to gain the crucial hallmarks of cancer. To allow selection of the most optimal ncRNA targets, a more systematic analysis of their functional networks in normal cells as well as in cancer cells needs to be performed to oversee the consequences of targeting them.

Currently, more and more institutes and companies investigate how to specifically target miRNAs and lncRNAs, using both antisense and small molecule-based strategies (Chakraborty *et al.*, 2017; Warner *et al.*, 2018). Inhibitors for miR-92 and miR-122, as well as mimics of miR-16, miR-29 and miR-34, have



been developed and tested or are currently tested in clinical trials (NIH U.S. National Library of Medicine, <https://clinicaltrials.gov/> (accessed 06.08.2018)). As miR-34a-5p has tumor suppressor activity by both targeting MYC and stimulating apoptosis, while repressing cell cycle progression and metastasis, it is an attractive target for novel anticancer therapies. MiR-16-5p and miR-29-3p too have tumor-suppressive roles in four of the five hallmarks discussed and form attractive targets as well. The cell type-specific expression of lncRNAs adds to their attractiveness as targets for therapy (Derrien *et al.*, 2012). The choice for an attractive target will therefore depend on the type of cancer. For example, CCAT1-L and CCAT2 form attractive targets to specifically inhibit MYC transcription in colorectal cancer. A drug against CCAT1-L, which will also target CCAT1-S, would be very interesting as it will inhibit cell cycle progression and metastasis, while promoting apoptosis. However, a main problem for testing effectivity of lncRNA-based drugs is the limited conservation for many of the lncRNAs, which prevents pre-clinical experiments in relevant mouse models. Patient-derived xenotransplantation models or organoid cultures might represent an alternative approach to test effectiveness of targeting human-specific lncRNAs.

Thus, although MYC is described as one of the most important oncogenes, it is important to realize that there is an extensive, multilayered ncRNA network around MYC, in which intricate crosstalk contributes to hallmarks of cancer.

## Acknowledgements

We would like to thank Emily Ploeg for her help with gathering literature and background information. This work was supported by grants from Lymph & Co (to AvdB and JK), the Dutch Cancer Society (KWF #10478/2016-1 to AvdB and JK) and the National Science Centre, Poland (2016/23/D/NZ1/01611 to AD-K).

## Author contributions

LJYMS, AD-K, AvdB, and JK conceived the outline, and LJYMS, AD-K, MW, AvdB, and JK wrote the manuscript. LJYMS, AD-K, and JK made the figures. LJYMS, AD-K, MW, AvdB, and JK critically read the manuscript and LJYMS, AvdB, and JK finalized the manuscript.

## Conflicts of interest

The authors have no conflicts of interest to declare.

## References

- Albihn A, Johnsen JI and Henriksson MA (2010) MYC in oncogenesis and as a target for cancer therapies. *Adv Cancer Res* **107**, 163–224.
- Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. *Cell* **136**, 215–233.
- Bolster DR, Crozier SJ, Kimball SR and Jefferson LS (2002) AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. *J Biol Chem* **277**, 23977–23980.
- Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB *et al.* (2007) p53-mediated activation of miRNA34 candidate tumor-suppressor genes. *Curr Biol* **17**, 1298–1307.
- Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C *et al.* (2008) The *miR-15a-miR-16-1* cluster controls prostate cancer by targeting multiple oncogenic activities. *Nat Med* **14**, 1271–1277.
- Bueno MJ, Gómez de Cedrón M, Gómez-López G, Pérez de Castro I, Di Lisio L, Montes-Moreno S, Martínez N, Guerrero M, Sánchez-Martínez R, Santos J *et al.* (2011) Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway. *Blood* **117**, 6255–6266.
- Cao L, Zhang P, Li J and Wu M (2017) LAST, a c-Myc-inducible long noncoding RNA, cooperates with CNBP to promote CCND mRNA stability in human cells. *Elife* **6**, e30433.
- Capizzi M, Strappazzon F, Cianfanelli V, Papaleo E, Cecconi F (2017) *MIR7-3HG*, a MYC-dependent modulator of cell proliferation, inhibits autophagy by a regulatory loop involving AMBRA1. *Autophagy* **13**, 554–566.
- Chakraborty C, Sharma AR, Sharma G, Doss CGP and Lee SS (2017) Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine. *Mol Ther Nucleic Acids* **8**, 132–143.
- Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, Dang CV, Thomas-Tikhonenko A, Mendell JT (2008) Widespread microRNA repression by Myc contributes to tumorigenesis. *Nat Genet* **40**, 43–50.
- Chang TC, Zeitels LR, Hwang HW, Chivukula RR, Wentzel EA, Dews M, Jung J, Gao P, Dang CV, Beer MA *et al.* (2009) Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. *Proc Natl Acad Sci U S A* **106**, 3384–3389.
- Chen L (2016) Linking long noncoding RNA localization and function. *Trends Biochem Sci* **41**, 761–772.
- Chen B, Liu Y, Jin X, Lu W, Liu J, Xia Z, Yuan Q, Zhao X, Xu N, Liang S (2014a) MicroRNA-26a regulates glucose metabolism by direct targeting PDHX in colorectal cancer cells. *BMC Cancer* **14**, 443–452.

- Chen S, Ma P, Li B, Zhu D, Chen X, Xiang Y, Wang T, Ren X, Liu C, Jin X (2017) LncRNA CCAT1 inhibits cell apoptosis of renal cell carcinoma through up-regulation of Livin protein. *Mol Cell Biochem*, **434**, 135–142.
- Chen D, Sun Y, Wei Y, Zhang P, Rezaeian AH, Teruya-Feldstein J, Gupta S, Liang H, Lin HK, Hung MC *et al.* (2012) LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. *Nat Med* **18**, 1511–1517.
- Chen L, Xiao H, Wang Z-H, Huang Y, Liu Z-P, Ren H, Song H (2014b) MiR-29a suppresses growth and invasion of gastric cancer cells *in vitro* by targeting VEGF-A. *BMB Rep* **47**, 39–44.
- Cho SW, Xu J, Sun R, Mumbach MR, Carter AC, Chen YG, Yost KE, Kim J, He J, Nevins SA *et al.* (2018) Promoter of lncRNA Gene PVT1 is a tumor-suppressor DNA boundary element. *Cell* **173**, 1398–1412.
- Choi Y, Yoon S, Jeong Y, Yoon J, Baek K (2011) Regulation of vascular endothelial growth factor signaling by miR-200b. *Mol Cells* **32**, 77–82.
- Chou Y-T, Lin H-H, Lien Y-C, Wang Y-H, Hong C-F, Kao Y-R, Lin S-C, Chang Y-C, Lin S-Y, Chen S-J *et al.* (2010) EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. *Cancer Res* **70**, 8822–8831.
- Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, Pilpel Y, Nielsen FC, Oren M, Lund AH (2010) p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. *Cell Death Differ* **17**, 236–245.
- Cianfanelli V, Fuoco C, Lorente M, Salazar M, Quondamatteo F, Gherardini PF, De Zio D, Nazio F, Antonioli M, D'Orazio M *et al.* (2015) AMBRA1 links autophagy to cell proliferation and tumorigenesis by promoting c-Myc dephosphorylation and degradation. *Nat Cell Biol* **17**, 20–30.
- Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M *et al.* (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. *Proc Natl Acad Sci U S A* **102**, 13944–13949.
- Cobbold LC, Spriggs KA, Haines SJ, Dobbyn HC, Hayes C, de MoorCH, Lilley KS, Bushell M, Willis AE (2008) Identification of internal ribosome entry segment (IRES)-trans-acting factors for the Myc family of IRESs. *Mol Cell Biol* **28**, 40–49.
- Craig VJ, Cogliatti SB, Imig J, Renner C, Neuenschwander S, Rehrauer H, Schlappach R, Dirnhofer S, Tzankov A, Müller A (2011) Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. *Blood* **117**, 6227–6236.
- Dang CV (2012) MYC on the path to cancer. *Cell* **149**, 22–35.
- Deng L, Yang S, Xu F, Zhang J (2015) Long noncoding RNA CCAT1 promotes hepatocellular carcinoma progression by functioning as let-7 sponge. *J Exp Clin Cancer Res* **34**, 18–27.
- Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG *et al.* (2012) The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. *Genome Res* **22**, 1775–1789.
- Dews M, Fox JL, Hultine S, Sundaram P, Wang W, Liu YY, Furth E, Enders GH, El-Deiry W, Schelter JM *et al.* (2010) Myc - miR-17-92 axis blunts TGF $\beta$  signaling and production of multiple TGF $\beta$ -dependent anti-angiogenic factors. *Cancer Res* **70**, 8233–8246.
- Ding L, Zhang Y, Han L, Fu L, Mei X, Wang J, Itkow J, Elabid AEI, Pang L, Yu D (2018) Activating and sustaining c-Myc by depletion of miR-144/451 gene locus contributes to B-lymphomagenesis. *Oncogene* **37**, 1293–1307.
- Doose G, Haake A, Bernhart SH, López C, Duggimpudi S, Wojciech F, Bergmann AK, Borkhardt A, Burkhardt B, Claviez A *et al.* (2015) MINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cells. *Proc Natl Acad Sci U S A* **112**, 5261–5270.
- Doose G, Hoffmann S, Iaccarino I (2016) Reply to Hart *et al.*: MINCR and MYC: more than expression correlation. *Proc Natl Acad Sci U S A* **113**, E498.
- Ernst A, Campos B, Meier J, Devens F, Liesenberg F, Wolter M, Reifemberger G, Herold-Mende C, Lichter P, Radlwimmer B (2010) De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures. *Oncogene* **29**, 3411–3422.
- Fang JH, Zhou HC, Zeng C, Yang J, Liu Y, Huang X, Zhang JP, Guan XY, Zhuang SM (2011) MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. *Hepatology* **54**, 1729–1740.
- Fei X, Qi M, Wu B, Song Y, Wang Y and Li T (2012) MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression. *FEBS Lett* **586**, 392–397.
- Feng M, Li Z, Aau M, Wong CH, Yang X and Yu Q (2011) Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation. *Oncogene* **30**, 2242–2251.
- Fox JL, Dews M, Minn AJ and Thomas-Tikhonenko A (2013) Targeting of TGF $\beta$  signature and its essential

- component CTGF by miR-18 correlates with improved survival in glioblastoma. *RNA* **19**, 177–190.
- Fu Y, Liu X, Zhou N, Du L, Sun Y, Zhang X, Ge Y (2014) MicroRNA-200b stimulates tumour growth in TGFBR2-null colorectal cancers by negatively regulating p27/kip1. *J Cell Physiol* **229**, 772–782.
- Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT *et al.* (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. *Nature* **458**, 762–765.
- Ge X-S, Ma H-J, Zheng X-H, Ruan H-L, Liao X-Y, Xue W-Q, Chen Y-B, Zhang Y, Jia W-H (2013) HOTAIR, a prognostic factor in esophageal squamous cell carcinoma, inhibits WIF-1 expression and activates Wnt pathway. *Cancer Sci* **104**, 1675–1682.
- Gong C, Li Z, Ramanujan K, Clay I, Zhang Y, Lemire-Brachat S, Glass DJ (2015) A long non-coding RNA, *LncMyoD*, regulates skeletal muscle differentiation by blocking IMP2-mediated mRNA translation. *Dev Cell* **34**, 181–191.
- Hahn S, Jackstadt R, Siemens H, Hüntten S and Hermeking H (2013) SNAI1 and miR-34a feed-forward regulation of ZNF281/ZBP99 promotes epithelial–mesenchymal transition. *EMBO J* **32**, 3079–3095.
- Han H, Li W, Shen H, Zhang J, Zhu Y and Li Y (2016) microRNA-129-5p, a c-Myc negative target, affects hepatocellular carcinoma progression by blocking the Warburg effect. *J Mol Cell Biol* **8**, 400–410.
- Han H, Sun D, Li W, Shen H, Zhu Y, Li C, Chen Y, Lu L, Li W, Zhang J *et al.* (2013) A c-Myc-MicroRNA functional feedback loop affects hepatocarcinogenesis. *Hepatology* **57**, 2378–2389.
- Hart JR, Roberts TC, Weinberg MS, Morris KV and Vogt PK (2014) MYC regulates the non-coding transcriptome. *Oncotarget* **5**, 12543–12554.
- Hart JR, Weinberg MS, Morris KV, Roberts TC, Janda KD, Garner AL, Vogt PK (2016) MINCR is not a MYC-induced lncRNA. *Proc Natl Acad Sci U S A* **113**, E496–E497.
- He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D *et al.* (2007) A microRNA component of the p53 tumour suppressor network. *Nature* **447**, 1130–1134.
- He X, Tan X, Wang X, Jin H, Liu L, Ma L, Yu H, Fan Z (2014) C-Myc-activated long noncoding RNA CCAT1 promotes colon cancer cell proliferation and invasion. *Tumor Biol* **35**, 12181–12188.
- He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ *et al.* (2005) A microRNA polycistron as a potential human oncogene. *Nature* **435**, 828–833.
- Hoffmann I (2000) The role of Cdc25 phosphatases in cell cycle checkpoints. *Protoplasma* **211**, 8–11.
- Hu T and Lu YR (2015) BCYRN1, a c-MYC-activated long non-coding RNA, regulates cell metastasis of non-small-cell lung cancer. *Cancer Cell Int* **15**, 36–43.
- Hua Z, Lv Q, Ye W, Wong C-KA, Cai G, Gu D, Ji Y, Zhao C, Wang J, Yang BB *et al.* (2006) MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. *PLoS One* **1**, e116.
- Huang W, Tian Y, Dong S, Cha Y, Li J, Guo X, Yuan X (2017) The long non-coding RNA SNHG3 functions as a competing endogenous RNA to promote malignant development of colorectal cancer. *Oncol Rep* **38**, 1402–1410.
- Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, Zhao BS, Mesquita A, Liu C, Yuan CL *et al.* (2018) Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. *Nat Cell Biol* **20**, 285–295.
- Huang J, Zhang A, Ho TT, Zhang Z, Zhou N, Ding X, Zhang X, Xu M, Mo YY (2015) Linc-RoR promotes c-Myc expression through hnRNP I and AUF1. *Nucleic Acid Res* **44**, 3059–3069.
- Hung CL, Wang LY, Yu YL, Chen HW, Srivastava S, Petrovics G, Kung HJ (2014) A long noncoding RNA connects c-Myc to tumor metabolism. *Proc Natl Acad Sci U S A* **111**, 18697–18702.
- Ivanovska I, Ball AS, Diaz RL, Magnus JF, Kibukawa M, Schelter JM, Kobayashi SV, Lim L, Burchard J, Jackson AL *et al.* (2008) MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. *Mol Cell Biol* **28**, 2167–2174.
- Jackstadt R, Jung P and Hermeking H (2013a) AP4 directly downregulates p16 and p21 to suppress senescence and mediate transformation. *Cell Death Dis* **15**, e775.
- Jackstadt R, Röh S, Neumann J, Jung P, Hoffmann R, Horst D, Berens C, Bornkamm GW, Kirchner T, Menssen A *et al.* (2013b) AP4 is a mediator of epithelial–mesenchymal transition and metastasis in colorectal cancer. *J Exp Med* **210**, 1331–1350.
- Jia P, Cai H, Liu X, Chen J, Ma J, Wang P, Liu Y, Zheng J, Xue Y (2016) Long non-coding RNA H19 regulates glioma angiogenesis and the biological behavior of glioma-associated endothelial cells by inhibiting microRNA-29a. *Cancer Lett* **381**, 359–369.
- Jiang C, Long J, Liu B, Xie X, Kuang M (2015) Mcl-1 is a novel target of miR-26b that is associated with the apoptosis induced by TRAIL in HCC cells. *Biomed Res Int* **2015**, 1–9.
- Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J *et al.* (2007) The *let-7* microRNA represses cell proliferation pathways in human cells. *Cancer Res* **67**, 7713–7722.
- Jung HM, Patel RS, Phillips BL, Wang H, Cohen DM, Reinhold WC, Chang LJ, Yang LJ, Chan EK (2013)

- Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions. *Mol Biol Cell* **24**, 1638–1648.
- Kalkat M, De Melo J, Hickman K, Lourenco C, Redel C, Resetca D, Tamachi A, Tu W, Penn L (2017) MYC deregulation in primary human cancers. *Genes* **8**, 151–180.
- Kawasaki Y, Komiya M, Matsumura K, Negishi L, Suda S, Okuno M, Yokota N, Osada T, Nagashima T, Hiyoshi M *et al.* (2016) MYU, a target lncRNA for Wnt/c-Myc signaling, mediates induction of CDK6 to promote cell cycle progression. *Cell Rep* **16**, 2554–2564.
- Kim T, Cui R, Jeon Y-, Fadda P, Alder H, Croce CM (2015a) MYC-repressed long noncoding RNAs antagonize MYC-induced cell proliferation and cell cycle progression. *Oncotarget* **6**, 18780–18789.
- Kim T, Cui R, Jeon Y-J, Lee J-H, Lee JH, Sim H, Park JK, Fadda P, Tili E, Nakanishi H *et al.* (2014) Long-range interaction and correlation between MYC enhancer and oncogenic long noncoding RNA CARLO-5. *Proc Natl Acad Sci U S A* **111**, 4173–4178.
- Kim T, Jeon Y-J, Cui R, Lee J-H, Peng Y, Kim S-H, Tili E, Alder H, Croce CM (2015b) Role of MYC-regulated long noncoding RNAs in cell cycle regulation and tumorigenesis. *J Natl Cancer Inst* **107**, dju505.
- Kim HH, Kuwano Y, Srikantan S, Lee EK, Martindale JL and Gorospe M (2009) HuR recruits let-7/RISC to repress c-Myc expression. *Genes Dev* **23**, 1743–1748.
- Kong YW, Cannell IG, de Moor CH, Hill K, Garside PG, Hamilton TL, Meijer HA, Dobbyn HC, Stoneley M, Spriggs KA *et al.* (2008) The mechanism of micro-RNA-mediated translation repression is determined by the promoter of the target gene. *Proc Natl Acad Sci U S A* **105**, 8866–8871.
- Korpai M, Lee ES, Hu G and Kang Y (2008) The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin Transcriptional Repressors *ZEB1* and *ZEB2*. *J Biol Chem* **283**, 14910–14914.
- Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR *et al.* (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. *Cell* **137**, 1005–1017.
- Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, O'Day E, Chowdhury D, Dykxhoorn DM, Tsai P, Hofmann O *et al.* (2009) miR-24 inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to “seedless” 3'UTR microRNA recognition elements. *Mol Cell* **35**, 610–625.
- Lee DY, Deng Z, Wang C and Yang BB (2007) MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. *Proc Natl Acad Sci U S A* **104**, 20350–20355.
- Lee YS and Dutta A (2007) The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. *Genes Dev* **21**, 1025–1030.
- Legesse-Miller A, Elemento O, Pfau SJ, Forman JJ, Tavazoie S, Collier HA (2009) let-7 Overexpression leads to an increased fraction of cells in G2/M, direct down-regulation of Cdc34, and stabilization of Wee1 kinase in primary fibroblasts. *J Biol Chem* **284**, 6605–6609.
- Li Y, Cai B, Shen L, Dong Y, Lu Q, Sun S, Liu S, Ma S, Ma PX, Chen J (2017b) MiRNA-29b suppresses tumor growth through simultaneously inhibiting angiogenesis and tumorigenesis by targeting Akt3. *Cancer Lett* **397**, 111–119.
- Li M, Chen H, Zhao Y, Gao S and Cheng C (2016) H19 functions as a ceRNA in promoting metastasis through decreasing miR-200s activity in osteosarcoma. *DNA Cell Biol* **35**, 235–240.
- Li L, Kang L, Zhao W, Feng Y, Liu W, Wang T, Mai H, Huang J, Chen S, Liang Y *et al.* (2017a) miR-30a-5p suppresses breast tumor growth and metastasis through inhibition of LDHA-mediated Warburg effect. *Cancer Lett* **400**, 89–98.
- Li X, Sanda T, Look AT, Novina CD and von Boehmer H (2011) Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL. *J Exp Med* **208**, 663–675.
- Liang WC, Fu WM, Wong CW, Wang Y, Wang WM, Hu GX, Zhang L, Xiao LJ, Wan DC, Zhang JF *et al.* (2015) The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. *Oncotarget* **6**, 22513–22525.
- Liao J, Liu H (2011) Autoregulatory suppression of c-Myc by miR-185-3p. *J Biol Chem* **286**, 33901–33909.
- Lin F, Ding R, Zheng S, Xing D, Hong W, Zhou Z, Shen J (2014) Decrease expression of microRNA-744 promotes cell proliferation by targeting c-Myc in human hepatocellular carcinoma. *Cancer Cell Int* **14**, 58–66.
- Lin CJ, Gong H, Tseng H, Wang W, Wu J (2008) miR-122 targets an anti-apoptotic gene, *Bcl-w*, in human hepatocellular carcinoma cell lines. *Biochem Biophys Res Comm* **375**, 315–320.
- Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gafà R, Song J, Guo Z *et al.* (2013) CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. *Genome Res* **23**, 1446–1461.
- Liu D, Dong L, Liu Y, Wen D, Gao D, Sun H, Fan J, Wu W (2016) A c-Myc/miR-17-5p feedback loop regulates metastasis and invasion of hepatocellular carcinoma. *Tumor Biol* **37**, 5039–5047.



- Liu Y, Huang H, Liu M, Wu Q, Li W and Zhang J (2017) MicroRNA-24-1 suppresses mouse hepatoma cell invasion and metastasis via directly targeting *O*-GlcNAc transferase. *Biomed Pharmacother* **91**, 731–738.
- Liu K, Li L, Rusidanmu A, Wang Y and Lv X (2015a) Down-regulation of MiR-1294 is related to dismal prognosis of patients with esophageal squamous cell carcinoma through elevating C-MYC expression. *Cell Physiol Biochem* **36**, 100–110.
- Liu Z, Sun M, Lu K, Liu J, Zhang M, Wu W, De W, Wang Z, Wang R (2013) The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregulation of p21<sup>WAF1/CIP1</sup> expression. *PLoS One* **8**, e77293.
- Liu Y, Sun M, Xia R, Zhang E, Liu X, Zhang Z, Xu T, De W, Liu B, Wang Z (2015b) LincHOTAIR epigenetically silences *miR34a* by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. *Cell Death Dis* **6**, e1802.
- Liu Z, Wu G, Lin C, Guo H, Xu J and Zhao T (2018) IGF2BP1 over-expression in skin squamous cell carcinoma cells is essential for cell growth. *Biochem Biophys Res Comm* **501**, 731–738.
- Liu B, Wu X, Liu B, Wang C, Liu Y, Zhou Q, Xu K (2012) MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. *Biochem Biophys Acta* **1822**, 1692–1704.
- Liu Z, Zhang G, Li J, Liu J and Lv P (2014) The tumor-suppressive microRNA-135b targets c-Myc in osteosarcoma. *PLoS One* **9**, e102621.
- López-Urrutia E, Coronel-Hernández J, García-Castillo V, Contreras-Romero C, Martínez-Gutierrez A, Estrada-Galicia D, Terrazas LI, López-Camarillo C, Maldonado-Martínez H, Jacobo-Herrera N *et al.* (2017) MiR-26a downregulates retinoblastoma in colorectal cancer. *Tumor Biol* **39**, 1010428317695945.
- Lu Y, Hu Z, Mangala LS, Stine ZE, Hu X, Jiang D, Xiang Y, Zhang Y, Pradeep S, Rodriguez-Aguayo C *et al.* (2018) MYC targeted long noncoding RNA DANCER promotes cancer in part by reducing p21 levels. *Cancer Res* **78**, 64–74.
- Luan W, Zhou Z, Ni X, Xia Y, Wang J, Yan Y, Xu B (2018) Long non-coding RNA H19 promotes glucose metabolism and cell growth in malignant melanoma via miR-106a-5p/E2F3 axis. *J Cancer Res Clin Oncol* **144**, 531–542.
- Luo M, Li Z, Wang W, Zeng Y, Liu Z and Qiu J (2013) Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. *Cancer Lett* **333**, 213–221.
- Luo L, Tang H, Ling L, Li N, Jia X, Zhang Z, Wang X, Shi L, Yin J, Qiu N *et al.* (2018) LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer. *Oncogene* **37**, 6166–6179.
- Lv Z, Wei J, You W, Wang R, Shang J, Xiong Y, Yang H, Yang X, Fu Z (2017) Disruption of the c-Myc/miR-200b-3p/PRDX2 regulatory loop enhances tumor metastasis and chemotherapeutic resistance in colorectal cancer. *J Transl Med* **15**, 257–274.
- Ma M, Li C, Zhang Y, Weng M, Zhang M, Qin Y, Gong W, Quan Z (2014) Long non-coding RNA HOTAIR, a c-Myc activated driver of malignancy, negatively regulates miRNA-130a in gallbladder cancer. *Mol Cancer* **13**, 156–169.
- Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S *et al.* (2010) miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. *Nat Cell Biol* **12**, 247–256.
- Ma Y, Zhou G, Li M, Hu D, Zhang L, Liu P, Lin K (2018) Long noncoding RNA DANCER mediates cisplatin resistance in glioma cells via activating AXL/PI3K/Akt/NF-κB signaling pathway. *Neurochem Int* **118**, 233–241.
- MacKenzie ED, Selak MA, Tennant DA, Payne LJ, Crosby S, Frederiksen CM, Watson DG, Gottlieb E (2007) Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. *Mol Cell Biol* **27**, 3282–3289.
- Maldotti M, Incarnato D, Neri F, Krepelova A, Rapelli S, Anselmi F, Parlato C, Basile G, Dettori D, Calogero R *et al.* (2016) The long intergenic non-coding RNA CCR492 functions as a let-7 competitive endogenous RNA to regulate c-Myc expression. *Biochem Biophys Acta* **1859**, 1322–1332.
- Marchese FP, Grossi E, Marín-Béjar O, Bharti SK, Raimondi I, González J, Martínez-Herrera DJ, Athie A, Amadoz A, Brosh RM Jr *et al.* (2016) A long noncoding RNA regulates sister chromatid cohesion. *Mol Cell* **63**, 397–407.
- Mavrikakis KJ, Wolfe AL, Oricchio E, Palomero T, de Keersmaecker K, McJunkin K, Zuber J, James T, Khan AA, Leslie CS *et al.* (2010) Genome-wide RNAi screen identifies miR-19 targets in Notch-induced acute T-cell leukaemia (T-ALL). *Nat Cell Biol* **12**, 372–379.
- Mayr C, Hemann MT and Bartel DP (2007) Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. *Science* **315**, 1576–1579.
- Miao L-J, Huang S-F, Sun Z-T, Gao Z-Y, Zhang R, Liu Y, Wang J (2013) MiR-449c targets c-Myc and inhibits NSCLC cell progression. *FEBS Lett* **587**, 1359–1365.
- Mogilyansky E and Rigoutsos I (2013) The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. *Cell Death Differ* **20**, 1603–1614.
- Mott JL, Kobayashi S, Bronk SF and Gores GJ (2007) mir-29 regulates Mcl-1 protein expression and apoptosis. *Oncogene* **26**, 6133–6140.



- Mu P, Han Y-C, Betel D, Yao E, Squatrito M, Ogrodowski P, de Stanchina E, D'Andrea A, Sander C, Ventura A (2009) Genetic dissection of the *miR-17~92* cluster of microRNAs in Myc-induced B-cell lymphomas. *Genes Dev* **23**, 2806–2811.
- Napoli S, Piccinelli V, Mapelli SN, Pisignano G and Catapano CV (2017) Natural antisense transcripts drive a regulatory cascade controlling c-MYC transcription. *RNA Biol* **14**, 1742–1755.
- O'Donnell KA, Wentzel EA, Zeller KI, Dang CV and Mendell JT (2005) c-Myc-regulated microRNAs modulate E2F1 expression. *Nature* **435**, 839–843.
- Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, Li QJ, Lowe SW, Hannon GJ, He L (2009) *miR-19* is a key oncogenic component of *mir-17-92*. *Genes Dev* **23**, 2839–2849.
- Park S, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. *Genes Dev* **22**, 894–907.
- Peng J, Hou F, Feng J, Xu S and Meng X (2018) Long non-coding RNA BCYRN1 promotes the proliferation and metastasis of cervical cancer via targeting microRNA-138 *in vitro* and *in vivo*. *Oncol Lett* **15**, 5809–5818.
- Peng F, Jiang J, Yu Y, Tian R, Guo X, Li X, Shen M, Xu M, Zhu F, Shi C *et al.* (2013) Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumorigenesis and metastasis. *Br J Cancer* **109**, 3092–3104.
- Peng F, Li T-T, Wang K-L, Xiao G-Q, Wang J-H, Zhao H-D, Kang Z-J, Fan W-J, Zhu L-L, Li M *et al.* (2017) H19/let-7/LIN28 reciprocal negative regulatory circuit promotes breast cancer stem cell maintenance. *Cell Death Dis* **8**, e2569.
- Petrocca F, Vecchione A and Croce CM (2008) Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor B signaling. *Cancer Res* **68**, 8191–8194.
- Pok S, Wen V, Shackel N, Alsop A, Pyakurel P, Fahrner A, Farrell GC, Teoh NC (2013) Cyclin E facilitates dysplastic hepatocytes to bypass G1/S checkpoint in hepatocarcinogenesis. *J Gastroenterol Hepatol* **28**, 1545–1554.
- Poyyakkara A, Raji GR, Kunhiraman H, Edatt L and Kumar SVB (2018) ER stress mediated regulation of miR23a confer HeLa cells better adaptability to utilize glycolytic pathway. *J Cell Biochem* **119**, 4907–4917.
- Prensner JR, Chen W, Han S, Iyer MK, Cao Q, Kothari V, Evans JR, Knudsen KE, Paulsen MT, Ljungman M *et al.* (2014) The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. *Neoplasia* **16**, 900–908.
- Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, Laxman B, Asangani IA, Grasso CS, Kominsky HD *et al.* (2011) Transcriptome sequencing across a prostate cancer cohort identifies *PCAT-1*, an unannotated lincRNA implicated in disease progression. *Nat Biotechnol* **29**, 742–749.
- Robertus J-L, Kluiver J, Weggemans C, Harms G, Reijmers RM, Swart Y, Kok K, Rosati S, Schuurin E, Van Imhoff G *et al.* (2010) MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma. *Br J Haematol* **149**, 896–918.
- Rogler CE, Levoci L, Ader T, Massimi A, Tchaikovskaya T, Norel R, Rogler LE (2009) MicroRNA-23b cluster microRNAs regulate transforming growth factor-beta/bone morphogenetic protein signaling and liver stem cell differentiation by targeting Smads. *Hepatology* **50**, 575–584.
- Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY (2009) p53 represses c-Myc through induction of the tumor suppressor miR-145. *Proc Natl Acad Sci U S A* **106**, 3207–3212.
- Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, Petrelli NJ, Dunn SP, Krueger LJ (2007) MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. *Cancer Res* **67**, 9762–9770.
- Schmitt AM and Chang HY (2016) Long noncoding RNAs in cancer pathways. *Cancer Cell* **29**, 452–463.
- Shen W, Liang X, Sun H, De Hoyos CL and Crooke ST (2017) Depletion of NEAT1 lncRNA attenuates nucleolar stress by releasing sequestered P54nrb and PSF to facilitate c-Myc translation. *PLoS One* **12**, e0173494.
- Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, Sun Z, Zheng X (2008) Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. *FEBS Lett* **582**, 1564–1568.
- Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F, Ferbeyre G, Chartrand P (2007) An E2F/miR-20a autoregulatory feedback loop. *J Biol Chem* **282**, 2135–2143.
- Takwi AA, Li Y, Becker Buscaglia LE, Zhang J, Choudhury S, Park AK, Liu M, Young KH, Park WY, Martin RC *et al.* (2012) A statin-regulated microRNA represses human c-Myc expression and function. *EMBO Mol Med* **4**, 896–909.
- Tania M, Khan MA and Fu J (2014) Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. *Tumor Biol* **35**, 7335–7342.
- Tanzer A and Stadler PF (2004) Molecular evolution of a microRNA cluster. *J Mol Biol* **339**, 327–335.
- Tran DDH, Kessler C, Niehus SE, Mahnkopf M, Koch A and Tamura T (2017) Myc target gene, long intergenic noncoding RNA, Linc00176 in hepatocellular carcinoma regulates cell cycle and cell survival by

- titrating tumor suppressor microRNAs. *Oncogene* **37**, 75–85.
- Trompeter HI, Abbad H, Iwaniuk KM, Hafner M, Renwick N, Tuschl T, Schira J, Müller HW, Wernet P (2011) MicroRNAs MiR-17, MiR-20a, and MiR-106b Act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC. *PLoS One* **6**, e16138.
- Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, Ronning P, Reuland B, Guenther K, Beadnell TC *et al.* (2014) PVT1 dependence in cancer with MYC copy-number increase. *Nature* **512**, 82–86.
- Tu WB, Helander S, Pilstål R, Hickman KA, Lourenco C, Jurisica I, Raught B, Wallner B, Sunnerhagen M, Penn LZ (2015) Myc and its interactors take shape. *Biochem Biophys Acta* **1849**, 469–483.
- Wang H, Cao F, Li X, Miao H, E J, Xing J, Fu C (2015) miR-320b suppresses cell proliferation by targeting c-Myc in human colorectal cancer cells. *BMC Cancer* **15**, 748–756.
- Wang F, Fu X, Zhou Y, Zhang Y (2009) Down-regulation of the cyclin E1 oncogene expression by microRNA-16-1 induces cell cycle arrest in human cancer cells. *BMB Rep* **42**, 725–730.
- Wang B, Hsu SH, Wang X, Kutay H, Bid HK, Yu J, Ganju RK, Jacob ST, Yuneva M, Ghoshal K (2014) Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: role of E2F1 and transcription factor dimerization partner 2. *Hepatology* **59**, 555–566.
- Wang D, Wang Y, Ma J, Wang W, Sun B, Zheng T, Wei M, Sun Y (2017a) MicroRNA-20a participates in the aerobic exercise-based prevention of coronary artery disease by targeting PTEN. *Biomed Pharmacother* **95**, 756–763.
- Wang O, Yang F, Liu Y, Lv L, Ma R, Chen C, Wang J, Tan Q, Cheng Y, Xia E *et al.* (2017b) C-MYC-induced upregulation of lncRNA SNHG12 regulates cell proliferation, apoptosis and migration in triple-negative breast cancer. *Am J Transl Res* **9**, 533–545.
- Wang S-H, Yang Y, Wu X-C, Zhang M-D, Weng M-Z, Zhou D, Wang J-D, Quan Z-W (2016) Long non-coding RNA MINCR promotes gallbladder cancer progression through stimulating EZH2 expression. *Cancer Lett* **380**, 122–133.
- Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, Jia L, Li S; Cancer Genome Atlas Research Network, Xie W *et al.* (2018) lncRNA epigenetic landscape analysis identifies *EPIC1* an oncogenic lncRNA that interacts with MYC and promotes cell-cycle progression in cancer. *Cancer Cell* **33**, 706–720.
- Warner KD, Hajdin CE, Weeks KM (2018) Principles for targeting RNA with drug-like small molecules. *Nat Rev Drug Discovery* **17**, 547–558.
- Winkle M, van den Berg A, Tayari M, Sietzema J, Terpstra M, Kortman G, de Jong D, Visser L, Diepstra A, Kok K *et al.* (2015) Long noncoding RNAs as a novel component of the Myc transcriptional network. *FASEB J* **29**, 2338–2346.
- Wong C-M, Wei L, Au L-KS, Fan N-YD, Zhou Y, Tsang H-CF, Law C-T, Lee M-FJ, He X, Shi J *et al.* (2015) MiR-200b/200c/429 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis. *Oncotarget* **6**, 13658–13670.
- Woods K, Thomson JM and Hammond SM (2007) Direct regulation of an oncogenic Micro-RNA cluster by E2F transcription factors. *J Biol Chem* **282**, 2130–2134.
- Xiang S, Gua H, Lei Jin L, Thorne RF, Zhang XD and Wua M (2018) LncRNA IDH1-AS1 links the functions of c-Myc and HIF1 $\alpha$  via IDH1 to regulate the Warburg effect. *Proc Natl Acad Sci U S A* **115**, 1465–1474.
- Xiang J-F, Yin Q-F, Chen T, Zhang Y, Zhang X-O, Wu Z, Zhang S, Wang H-B, Ge J, Lu X *et al.* (2014) Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. *Cell Res* **24**, 513–531.
- Xiao Z-D, Han L, Lee H, Zhuang L, Zhang Y, Baddour J, Nagrath D, Wood CG, Gu J, Wu X *et al.* (2017) Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy metabolism and inhibits renal tumor development. *Nat Commun* **8**, 783–795.
- Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, Henderson JM, Kutok JL, Rajewsky K (2008) Lymphoproliferative disease and autoimmunity in mice with elevated miR-17–92 expression in lymphocytes. *Nat Immunol* **9**, 405–414.
- Xiong J, Du Q and Liang Z (2010) Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. *Oncogene* **29**, 4980–4988.
- Xiong J, Wei B, Ye Q, Liu W (2016) MiR-30a-5p/UBE3C axis regulates breast cancer cell proliferation and migration. *Biochem Biophys Res Comm* pii: S0006-291X(16)30381-3. Epub ahead of print.
- Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP and Zhuang SM (2009) MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. *Hepatology* **50**, 113–121.
- Yang X, Liang L, Zhang X-F, Jia H-L, Qin Y, Zhu X-C, Gao X-M, Qiao P, Zheng Y, Sheng Y-Y *et al.* (2013b) MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. *Hepatology* **58**, 158–170.
- Yang W, Ning N and Jin X (2017) The lncRNA H19 promotes cell proliferation by competitively binding to miR-200a and Derepressing  $\beta$ -catenin expression in colorectal cancer. *Biomed Res Int* **2017**, 2767484.
- Yang F, Xue X, Bi J, Zheng L, Zhi K, Gu Y, Fang G (2013a) Long noncoding RNA CCAT1, which could be

- activated by c-Myc, promotes the progression of gastric carcinoma. *J Cancer Res Clin Oncol* **139**, 437–445.
- Yang F, Xue X, Zheng L, Bi J, Zhou Y, Zhi K, Gu Y, Fang G (2014) Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability. *FEBS J* **281**, 802–813.
- Yang X, Ye H, He M, Zhou X, Sun N, Guo W, Lin X, Huang H, Lin Y, Yao R *et al.* (2018) LncRNA PDIA3P interacts with c-Myc to regulate cell proliferation via induction of pentose phosphate pathway in multiple myeloma. *Biochem Biophys Res Comm* **498**, 207–213.
- Ye X, Huang H, Huang W and Hu W (2018) LncRNA THOR promotes human renal cell carcinoma cell growth. *Biochem Biophys Res Comm* **501**, 661–667.
- Yu Z, Wang C, Wang M, Li Z, Casimiro MC, Liu M, Wu K, Whittle J, Ju X, Hyslop T *et al.* (2008) A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. *J Cell Biol* **182**, 509–517.
- Zhang P, Cao L, Fan P, Mei Y and Wu M (2016a) LncRNA-MIF, a c-Myc-activated long non-coding RNA, suppresses glycolysis by promoting Fbxw7-mediated c-Myc degradation. *EMBO Rep* **17**, 1204–1220.
- Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski LC, Dalton WS, Seto E, Wright K, Sotomayor E *et al.* (2012a) Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. *Oncogene* **31**, 3002–3008.
- Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE *et al.* (2012b) Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas. *Cancer Cell* **22**, 506–523.
- Zhang Z, Zhou C, Chang Y, Zhang Z, Hu Y, Zhang F, Lu Y, Zheng L, Zhang W, Li X *et al.* (2016b) Long non-coding RNA CASC11 interacts with hnRNP-K and activates the WNT/ $\beta$ -catenin pathway to promote growth and metastasis in colorectal cancer. *Cancer Lett* **376**, 62–73.
- Zhao J and Cheng L (2017) Long non-coding RNA CCAT1/miR-148a axis promotes osteosarcoma proliferation and migration through regulating PIK3IP1. *Acta Biochim Biophys Sin* **49**, 503–512.
- Zhao J-J, Lin J, Lwin T, Yang H, Guo J, Kong W, Dessureault S, Moscinski LC, Rezanian D, Dalton WS *et al.* (2010) MicroRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. *Blood* **115**, 2630–2639.
- Zhao X, Lwin T, Zhang X, Huang A, Wang J, Marquez VE, Chen-Kiang S, Dalton WS, Sotomayor E, Tao J (2013) Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. *Leukemia* **27**, 2341–2350.
- Zhen Y, Liu Z, Yang H, Yu X, Wu Q, Hua S, Long X, Jiang Q, Song Y, Cheng C *et al.* (2013) Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma. *Cell Death Dis* **4**, e872.
- Zhou Q, Han LR, Zhou YX and Li Y (2016) MiR-195 suppresses cervical cancer migration and invasion through targeting Smad3. *Int J Gynecol Cancer* **26**, 817–824.
- Zhou W, Ye X, Xu J, Cao M-G, Fang Z-Y, Li L-Y, Guan G-H, Liu Q, Qian Y-H, Xie D (2017) The lncRNA H19 mediates breast cancer cell plasticity during EMT and MET plasticity by differentially sponging miR-200b/c and let-7b. *Sci Signal* **10**, eaak9557.
- Zhu Y, Lu Y, Zhang Q, Liu J-J, Li T-J, Yang J-R, Zeng C, Zhuang S-M (2012) MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. *Nucleic Acid Res* **40**, 4615–4625.
- Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, Oeh J, Modrusan Z, Bais C, Sampath D *et al.* (2012) Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. *EMBO J* **31**, 3513–3523.